Your browser doesn't support javascript.
loading
Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland.
Piccoli, Luca; Ferrari, Paolo; Piumatti, Giovanni; Jovic, Sandra; Rodriguez, Blanca Fernandez; Mele, Federico; Giacchetto-Sasselli, Isabella; Terrot, Tatiana; Silacci-Fregni, Chiara; Cameroni, Elisabetta; Jaconi, Stefano; Sprugasci, Nicole; Bartha, Istvan; Corti, Davide; Uguccioni, Mariagrazia; Lanzavecchia, Antonio; Garzoni, Christian; Giannini, Olivier; Bernasconi, Enos; Elzi, Luigia; Albanese, Emiliano; Sallusto, Federica; Ceschi, Alessandro.
Affiliation
  • Piccoli L; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Ferrari P; Department of Internal Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Piumatti G; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.
  • Jovic S; Clinical School, University of New South Wales, Sydney, Australia.
  • Rodriguez BF; Division of Primary Care, Population Epidemiology Unit, Geneva University Hospitals, Geneva, Switzerland.
  • Mele F; nstitute of Public Health, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
  • Giacchetto-Sasselli I; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Terrot T; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Silacci-Fregni C; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Cameroni E; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Jaconi S; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.
  • Sprugasci N; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Bartha I; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Corti D; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Uguccioni M; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Lanzavecchia A; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Garzoni C; Humabs BioMed SA, A Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
  • Giannini O; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Bernasconi E; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (Milan), Italy.
  • Elzi L; Institute for Research in Biomedicine, Bellinzona, Università della Svizzera italiana, Bellinzona, Switzerland.
  • Albanese E; Clinic of Internal Medicine and Infectious Diseases, Clinica Luganese Moncucco, Lugano, Switzerland.
  • Sallusto F; Department of Infectious Diseases, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Ceschi A; Department of Internal Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Lancet Reg Health Eur ; 1: 100013, 2021 Feb.
Article in En | MEDLINE | ID: mdl-34173621
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Risk_factors_studies Language: En Journal: Lancet Reg Health Eur Year: 2021 Document type: Article Affiliation country: Suiza Country of publication: Reino Unido
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Etiology_studies / Risk_factors_studies Language: En Journal: Lancet Reg Health Eur Year: 2021 Document type: Article Affiliation country: Suiza Country of publication: Reino Unido